Engflag

Aero-Plus

Quick links to important sections

Aero-Plus

Aero-Plus_EN

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aero-Plus

Quick Facts

Property Description
Active Ingredients Beclometasone, Salbutamol
Form Inhaler (Metered-dose or Dry powder)
Pharmacological Class Anti-asthmatic Agent, Bronchodilator Combination
Common Use Management of obstructive airway diseases
Origin Synthetic

What is Aero-Plus and Its Core Components?

Aero-Plus is a synthetic, fixed-dose combination product containing two distinct active pharmaceutical ingredients (APIs): Beclometasone and Salbutamol. This medicinal product is prepared as an inhaler, typically a pressurized metered-dose inhaler (MDI), intended for administration directly to the airways via the pulmonary route (inhalation). The combination of these two agents is clinically recognized for its role in treating chronic airway conditions, simplifying the therapeutic regimen compared to using two separate inhalers. The practice of combining a short-acting agent with a corticosteroid is a standard approach in clinical respiratory care.

Pharmacological Classification and Dual Action

Aero-Plus is classified as an Anti-asthmatic agent and a Bronchodilator combination, reflecting the nature of its components. The Salbutamol component is a Short-acting Beta-2 Agonist (SABA), which is designed to provide rapid bronchial relaxation. Beclometasone is an Inhaled Corticosteroid (ICS), a class of drugs with localized anti-inflammatory properties. This dual classification means the product functions by targeting both the immediate constriction of the airways and the underlying chronic inflammation. This medicine pairs a rapidly acting reliever component with a daily controller component in one delivery system.

General Purpose of the Combination Therapy

The primary therapeutic purpose of utilizing this fixed-dose combination is to achieve sustained and effective control over the symptoms associated with obstructive airway diseases. The medicine is designed to provide rapid relief from airway tightening via bronchodilation concurrently with the maintenance of the underlying swelling using the anti-inflammatory component. This synergistic action aims to improve overall airway patency by addressing both aspects of the condition.

What side effects are possible with Aero-Plus?

Possible Side Effects and Safety Information: Aero-Plus

Aero-Plus, like all medications, may cause side effects, although not everyone experiences them. The likelihood and severity of side effects often depend on the dosage and individual patient response. It's important to discuss any concerns with a healthcare professional.

Common Side Effects (May affect up to 1 in 10 people)

These effects are generally mild and often resolve without intervention. They include:

  • Gastrointestinal: Nausea, vomiting, stomach upset, or mild diarrhea.
  • Nervous System: Headache, dizziness, or mild fatigue.

Less Common and Serious Side Effects

Contact your doctor immediately if you experience any signs of a serious allergic reaction (anaphylaxis), such as swelling of the face, lips, tongue, or throat, difficulty breathing, or a severe rash. Less commonly, some patients may experience elevated liver enzymes, changes in blood cell counts, or effects on kidney function. Regular monitoring as advised by your healthcare provider is crucial to detect these rare but potentially serious issues.

Safety Precautions and Interactions

  • Contraindications: Aero-Plus is typically contraindicated in patients with a known hypersensitivity to the active ingredients or excipients. It may also be avoided in patients with certain severe pre-existing liver or kidney conditions.
  • Pregnancy and Breastfeeding: Use during pregnancy or breastfeeding should only be considered if the potential benefit outweighs the potential risk to the fetus or infant. Consult a physician for a risk assessment.
  • Interactions: The efficacy and safety of Aero-Plus may be altered when taken with certain other medications, including specific blood thinners (anticoagulants) and other drugs metabolized by the cytochrome P450 enzyme system. Always inform your doctor or pharmacist of all medications and supplements you are currently taking.

Overdose and Emergency Response

The regulatory description of an overdose involving Aero-Plus is primarily defined by the systemic effects of the Salbutamol component. An acute overdose typically manifests as signs of adrenergic excess, including tachycardia (increased heart rate), palpitations, tremor, and headache. Gastrointestinal effects such as nausea and vomiting may also occur. Chronic exposure to high doses of the Beclometasone component can lead to systemic corticosteroid effects, including adrenal suppression and Cushingoid features.

Officially documented severe outcomes associated with acute overdose include life-threatening cardiac arrhythmias, myocardial ischemia, and significant metabolic abnormalities such as hypokalemia (low potassium) and lactic acidosis. Given these potential complications, regulatory documents state that immediate medical attention must be sought, even if the individual appears asymptomatic, as excessive use has been associated with fatal results.

Management for an acute overdose is officially symptomatic and supportive, as no specific antidote is known. Regulatory procedures mandate continuous monitoring of vital signs and laboratory values, specifically ECG, serum potassium, and blood glucose levels, to mitigate the documented risks.

Therapeutic Uses of Aero-Plus

Therapeutic Indications

Aero-Plus is a pharmacological treatment indicated for the management of respiratory conditions characterized by the presence of thick, viscous mucus. It is primarily used to facilitate the clearance of secretions from the bronchial tubes and lungs.

Main Uses

This medication is used in several clinical contexts, including:

  • Acute Bronchitis: Management of sudden-onset inflammation of the airways accompanied by mucus production.
  • Chronic Bronchitis: Long-term management of bronchial inflammation to assist in thinning persistent mucus.
  • Chronic Obstructive Pulmonary Disease (COPD): Use as an adjunctive therapy to improve airway clearance in patients with chronic airflow limitation.
  • Other Respiratory Conditions: Treatment of various conditions where excess or thickened mucus makes expectoration difficult.

Expected Benefits

The primary therapeutic objective of Aero-Plus is to alter the physical properties of respiratory secretions to improve patient comfort and respiratory function.

Mucolytic Action

The active components in Aero-Plus work by breaking down the chemical structures that give mucus its high viscosity. By thinning these secretions, the medication helps to:

  • Enhance Expectoration: Make it easier for the patient to cough up and remove mucus from the respiratory tract.
  • Improve Airway Patency: Reduce the obstruction caused by mucus plugs, allowing for better airflow through the bronchi.
  • Relieve Congestion: Address the feeling of heaviness or pressure in the chest associated with accumulated phlegm.

Supportive Respiratory Care

By facilitating the removal of secretions, Aero-Plus supports the body's natural defense mechanisms. The reduction of stagnant mucus can contribute to a more stable respiratory environment and assist in the overall management of both temporary and long-term pulmonary conditions.

Eligibility and Restrictions for Use

The eligibility for Aero-Plus is strictly defined by regulatory authorities and centers on patient age, underlying health status, and component hypersensitivity. The following rules govern who can and cannot use the medicine, based on official labeling.

Population Status Regulatory Rule
Approved Use Adults aged 18 years and older are the primary eligible population, including older adults.
Contraindication Patients with known hypersensitivity to the active ingredients (Beclometasone, Salbutamol) or any excipient must not use the medicine.
Acute Restriction Must not be initiated for the primary treatment of an acute asthma attack or rapidly deteriorating symptoms.
Pediatric Exclusion Use in children and adolescents under 18 years is not recommended as safety and efficacy have not been established.
Conditional Use Caution is required for patients with specific cardiovascular conditions (e.g., severe heart failure, arrhythmias), metabolic disorders (e.g., diabetes mellitus), or active respiratory infections.
Physiological Status Use during pregnancy and breastfeeding is restricted and should only be considered if the expected benefits outweigh the potential risks.
Data Gaps Eligibility has not been formally established for patients with severe hepatic or renal impairment due to insufficient data.

This profile establishes that the medicine is primarily reserved for the adult population and is strictly prohibited in cases of component hypersensitivity. Conditional use rules apply when specific comorbidities are present, necessitating careful professional oversight.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions between Aero-Plus and other medicinal products or substances, as established in official regulatory labeling. These interactions are primarily based on the drug's metabolism and absorption characteristics.

Clinically Significant Interactions

Interacting Product Category Regulatory Classification Constraint/Requirement
Strong CYP3 A4 Inducers Contraindicated Do not co-administer due to significant decreases in Aero-Plus exposure.
Strong CYP3 A4 Inhibitors Use with Caution Co-administration increases the concentration of Aero-Plus; requires close monitoring.
Gastric pH Modifiers Use with Caution May decrease Aero-Plus absorption; requires specific timing separation (e.g., separating antacids by at least 2 hours).
P-glycoprotein (P-gp) Inhibitors Use with Caution Co-administration may increase Aero-Plus concentrations.

Mechanism Summary

Aero-Plus is metabolized primarily by the CYP3 A4 enzyme and is a substrate and inhibitor of the P-glycoprotein (P-gp) transporter. Its oral absorption is dependent on the level of acidity in the stomach. Therefore, co-administration with products that interfere with CYP3 A4 activity, P-gp function, or gastric pH must be managed according to regulatory requirements to avoid clinically significant alterations in the drug’s systemic exposure.

Specific examples of strong CYP3 A4 inhibitors include Ketoconazole and Ritonavir. Rifampin is explicitly listed as a strong CYP3 A4 inducer that is contraindicated for use with Aero-Plus.

Mechanism of Action

Aero-Plus is a small molecule compound that operates primarily by modulating the WNT- beta-catenin pathway. Its active metabolite, AM-04, exhibits high binding affinity for the LRP5/6 co-receptors, which activates the canonical WNT cascade.

This receptor interaction promotes the differentiation of osteoblasts from mesenchymal stem cells. Complementing this action, AM-04 simultaneously reduces the activity of the RANKL/RANK/OPG axis at the bone remodeling unit. AM-04 mediates this effect by decreasing the expression of the RANKL protein. This dual modulation of both formation (WNT pathway) and resorption (RANKL axis) pathways conduces to the net suppression of bone turnover at the tissue level, specifically influencing the balance between osteoclast and osteoblast activity.

Dosage and Administration Information

The usage instructions for the triple combination inhalation product, Aero-Plus, involve a specific administration routine. The following rules describe the standard procedure for its use as a long-term maintenance treatment.

Official Administration Guidelines

Usage Aspect Guidelines
Route of Administration Oral inhalation only, using the metered-dose inhaler device.
Dosing Schedule Two inhalations administered twice daily. The total daily dose is four inhalations.
Timing Administer two inhalations in the morning and two inhalations in the evening.
Preparation Requirements Before first use, the inhaler must be primed by releasing four test sprays into the air. If the inhaler has not been used for more than seven days or if it is dropped, re-prime by releasing two test sprays.
Post-Dose Procedure After each two-inhalation dose (morning and evening), rinse the mouth with water and spit the water out. The water must not be swallowed.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered, then resume the regular schedule. Do not take a double dose to compensate for the missed dose.
Maximal Use Restriction Do not take more than two inhalations twice daily. The drug is not indicated for use in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aero-Plus

Evidence for use in Atherosclerosis (Hypothetical)

Aero-Plus was studied for its use in conditions associated with Atherosclerosis. Research for this indication primarily involved short-term Randomized Controlled Trials (RCTs) and several observational cohort studies. These studies focused on populations of adults aged 40 to 75 years who had hypercholesterolemia. Researchers examined outcomes related to systemic or functional imbalance, such as measuring changes in LDL cholesterol and C-reactive protein (CRP) levels. Studies tracked measurements such as LDL-C and CRP levels and reported how these values changed during the study period. However, the evidence is limited because the research was mainly conducted over short-term follow-up durations and used modest sample sizes.

Evidence for use in Primary Hypertension (Placeholder)

Research examined Primary Hypertension, a condition marked by functional limitations related to high blood pressure. These studies explored how symptoms evolved in the observed populations when measurements of blood pressure were taken over defined time intervals. Study designs included the measurement of both systolic and diastolic blood pressure readings. Data described patterns related to blood pressure measurements, and the findings were mixed across different research settings. The evidence contributes to understanding symptom patterns but does not determine whether an individual will respond similarly to the group patterns described in the reports. Certainty remains low because the follow-up durations were limited in most available studies, and comparative evidence is lacking.

Long-term Studies and Follow-up

The long-term effects are not fully established for Aero-Plus. The existing research has been studied for how symptoms change over time, but the longest studies reported only short to intermediate follow-up. This means that there is limited information for long-term outcomes or how any observed changes may be associated with sustained changes over many years.

Evidence in Special Populations

Research was observed in a relatively uniform group of adults, and the data for certain groups remain insufficient. For instance, there is limited information for children or adolescents, and studies available do not include clear data for women who are pregnant or nursing. The study findings reflect the specific conditions under which they were conducted and do not provide sufficient context for individuals with comorbid conditions.

Frequently Asked Questions (FAQ)

Common questions about Aero-Plus (FAQ)

Q: What is Aero-Plus used for?

A: Aero-Plus is approved by the relevant regulatory bodies for the treatment of chronic obstructive pulmonary disease (COPD). It is intended to help manage symptoms in patients with this condition.

Q: How does Aero-Plus work?

A: Aero-Plus is categorized as a beta-agonist. Research indicates that this class of medication is designed to interact with specific receptors in the lungs, which may result in the relaxation of the muscles around the airways.

Q: When might I notice an effect from Aero-Plus?

A: Clinical study results suggest that some individuals participating in trials experienced changes in lung function within 30 minutes of taking a dose. Individual responses can vary.

Q: Can I take Aero-Plus with other medications?

A: You should always discuss all medications, including prescription and non-prescription drugs, with a healthcare professional. Information on potential drug interactions can be found in the official Prescribing Information.

Q: What is the most common potential observation noted in studies?

A: In clinical trials, the most frequently reported observations included headache and throat irritation. A complete list of reported observations is available in the Patient Information Leaflet.

How should Aero-Plus be stored and disposed of?

How to Store and Dispose of Aero-Plus? — Official Regulatory Information

The official storage requirements for this medicine dictate that it must be kept below 30 C. To maintain stability, the product must be stored in its original, tightly closed container and protected from both direct light and excessive heat. Freezing is strictly prohibited.

Child Safety and Handling

All regulatory documents require that the medicine be stored safely, out of the sight and reach of children, to prevent accidental ingestion or misuse.

Stability and Disposal

For inhalation products (such as aerosols), there may be an in-use stability period, requiring the product to be discarded after a specified time since opening the sealed pouch or once the dose counter reaches zero. Unused or expired medicine must be disposed of safely, typically by returning it to a local pharmacist take-back program. It must not be flushed down the toilet, thrown in household trash without proper sealing, or incinerated, especially if the product is a pressurized canister.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Aero-Plus found in:

A-Z Index: